UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/779,439	02/13/2004	Stefanie Flohr	DEAV2003/0072 US NP	8764
⁵⁴⁸⁷ ANDREA Q. R	7590 03/05/200 XYAN	EXAMINER		
SANOFI-AVE	NTIS U.S. LLC	WARD, PAUL V		
1041 ROUTE 202-206 MAIL CODE: D303A		ART UNIT	PAPER NUMBER	
BRIDGEWATER, NJ 08807			1624	
			NOTIFICATION DATE	DELIVERY MODE
			03/05/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPatent.E-Filing@sanofi-aventis.com andrea.ryan@sanofi-aventis.com

	Application No.	Applicant(s)				
	10/779,439	FLOHR ET AL.				
Office Action Summary	Examiner	Art Unit				
	PAUL V. WARD	1624				
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address				
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <u>26 No</u>	ovember 2008					
	action is non-final.					
·=						
closed in accordance with the practice under E	•					
Disposition of Claims						
4)⊠ Claim(s) <u>1-5,9 and 13</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5)⊠ Claim(s) <u>9 and 13</u> is/are allowed.						
6) Claim(s) <u>1-5</u> is/are rejected.						
7) ☐ Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers						
9) The specification is objected to by the Examine	r					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correct						
11)☐ The oath or declaration is objected to by the Ex		• •				
Priority under 35 U.S.C. § 119						
12) ☐ Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)	-(d) or (f).				
a) All b) Some * c) None of:						
1.☐ Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da 5) Notice of Informal P					
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 9/12/05.	5) Notice of Informal P 6) Other:	αιστι πρριισαιιστι				

DETAILED ACTION

STATUS OF THE CLAIMS: Claims 1-5, 9 and 13 are pending in this application.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on November 26, 2008 has been entered.

Response to Amendment Regarding

Claim Rejections - 35 USC § 112, 1st paragraph

1. The rejections, of claims 6, 9 and 13, have been overcome by Applicant's amendment in the reply filed November 26, 2008.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. Claims 1-5 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1-4 define variables (where applicable—e.g., R₁₁-R₁₅) as aryl, heterocycle/heterocyclic. The terms are indefinite since the specification does not

Application/Control Number: 10/779,439 Page 3

Art Unit: 1624

define the ring size, heteroatom(s), number and nature of substituents, and the exact point of contact with the atom(s) for the substituents. Correction is required.

Claim 5 is rejected because it is dependent claims dependent on a rejected independent claim.

Allowable Subject Matter

3. The compounds and the pharmaceutical composition in Claims 1-5 were not found to be obvious or anticipated by the prior art of record. The prior art does not teach or suggest the nitrogen substituted hexahydropyrazino [1,2-a]pyrimidine-4,7-dione compounds substituted in the manner claimed by the Applicant. Therefore, these claims will be allowed, if amended to overcome the rejection under 35 U.S.C. 112, 2nd paragraph. The methods of claims 9 and 13 were not found to be obvious nor anticipated by the prior art of record. The prior art does not teach or suggest the methods comprising the nitrogen substituted hexahydropyrazino [1,2-a]pyrimidine-4,7-dione compounds substituted in the manner claimed by the Applicant. Therefore, these claims are allowed.

Conclusion

Claims 1-5, 9 and 13 are pending. Claims 1-5 are rejected. Claims 9 and 13 are allowed.

Application/Control Number: 10/779,439 Page 4

Art Unit: 1624

Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL V WARD whose telephone number is 571-272-2909. The examiner can normally be reached on M-F 8 am to 4 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/PAUL V WARD/ Examiner, Art Unit 1624 /James O. Wilson/ Supervisory Patent Examiner, Art Unit 1624